On October 4, 2023 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported the company will present new clinical data for two of its RAS(ON) Inhibitors and other investigational compounds at upcoming oncology conferences, the 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) ("Triple Meeting") in Boston, Massachusetts, to be held October 11-15, and the 2023 European Society for Medical Oncology Congress (ESMO) (Free ESMO Whitepaper) in Madrid, Spain, to be held October 20-24 (Press release, Revolution Medicines, OCT 4, 2023, View Source [SID1234635647]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the Triple Meeting, the company will present the first report of clinical activity for RMC-6291, its RASG12C(ON) Inhibitor and additional preliminary safety and pharmacokinetic profiles for RMC-6236, its RASMULTI(ON) Inhibitor. At ESMO (Free ESMO Whitepaper), the company will present additional preliminary antitumor activity data for RMC-6236 in patients with non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC) carrying common KRASG12X mutations. The abstract related to this presentation, which will go live on the ESMO (Free ESMO Whitepaper) website at 0:05 CEST on October 16, 2023 (6:05 p.m. ET, October 15), will include data from an April 24, 2023 data extraction, while the Proffered Paper presentation itself will include more recent data from an October data extraction.

Shortly following the company’s ESMO (Free ESMO Whitepaper) data presentation, the company will host an investor webcast to review the clinical data presentations on RMC-6236 and RMC-6291, related clinical development vision, and the company’s overall pipeline and strategy.

Details of the presentations referenced above, as well as other presentations by the company at these conferences, are listed below:

Triple Meeting Oral Presentations:

Title: Targeting RAS-addicted cancers with investigational RAS(ON) inhibitors
Presenter: W. Clay Gustafson, M.D.
Session: Plenary Session 3: KRAS
Date/Time: 8:00 – 9:40 a.m. ET on October 13, 2023

Title: Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class,
RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant
solid tumors on the Phase 1 trial RMC-6236-001
Presenter: Alexander I. Spira
Abstract Number: B032*
Session: Plenary Session 4: New Drugs on the Horizon
Date/Time: 9:40 – 11:45 a.m. ET on October 13, 2023
*Also included in Poster Session B on October 13, from 12:30 to 4:00 p.m. ET.

Title: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex
KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor
treatment
Presenter: Pasi A. Jänne
Abstract Number: LB_B01*
Session: Spotlight on Proffered Papers 2
Date/Time: 11:50 a.m. – 12:20 p.m. ET on October 13, 2023
*Also included in Poster Session B on October 13, from 12:30 to 4:00 p.m. ET.

Triple Meeting Poster Presentations:

Title: Selective inhibition of the active state of KRASG12V with the non-covalent, tri-complex
Inhibitor RM-048
Presenter: Bianca J. Lee, Ph.D.
Abstract Number: B137
Session: Poster Session B
Date/Time: 12:30 – 4:00 p.m. ET on October 13, 2023

Title: First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors
Presenter: Alison M. Schram, M.D.
Abstract Number: C020
Session: Poster Session C
Date/Time: 12:30 – 4:00 p.m. ET on October 14, 2023

Additional information on the Triple Meeting is available through the conference website at: View Source

ESMO Oral Presentation:

Title: Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Presenter: Kathryn C. Arbour, M.D.
Abstract Number: 6520
Session: Proffered Paper Session – Developmental Therapeutics
Date/Time: 08:30 – 10:00 a.m. CEST (2:30 – 4:00 a.m. ET) on October 22, 2023

Additional information on the ESMO (Free ESMO Whitepaper) Congress is available through the conference website at: View Source

Investor Webcast
Revolution Medicines will host an investor webcast on Sunday, October 22, 2023, at 12:30 p.m. ET. The presentation will review the clinical data presentations on RMC-6236 and RMC-6291 highlighted above, related clinical development vision, and the company’s overall pipeline and strategy. To participate in the live webcast, participants may register in advance here: View Source A live webcast of the call will also be available on the Investors section of Revolution Medicines’ website at View Source Following the live webcast, a replay will be available on the company’s website for at least 14 days.